Computational Prediction of Blood-Brain Barrier Permeability Using Decision Tree Induction

Predicting blood-brain barrier (BBB) permeability is essential to drug development, as a molecule cannot exhibit pharmacological activity within the brain parenchyma without first transiting this barrier. Understanding the process of permeation, however, is complicated by a combination of both limited passive diffusion and active transport. Our aim here was to establish predictive models for BBB drug permeation that include both active and passive transport. A database of 153 compounds was compiled using in vivo surface permeability product (logPS) values in rats as a quantitative parameter for BBB permeability. The open source Chemical Development Kit (CDK) was used to calculate physico-chemical properties and descriptors. Predictive computational models were implemented by machine learning paradigms (decision tree induction) on both descriptor sets. Models with a corrected classification rate (CCR) of 90% were established. Mechanistic insight into BBB transport was provided by an Ant Colony Optimization (ACO)-based binary classifier analysis to identify the most predictive chemical substructures. Decision trees revealed descriptors of lipophilicity (aLogP) and charge (polar surface area), which were also previously described in models of passive diffusion. However, measures of molecular geometry and connectivity were found to be related to an active drug transport component.

[1]  A. Schinkel,et al.  P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. , 1996, The Journal of clinical investigation.

[2]  W. Pardridge,et al.  Log(BB), PS products and in silico models of drug brain penetration. , 2004, Drug discovery today.

[3]  Y. Takasato,et al.  Kinetics of Amino Acid Transport at the Blood‐Brain Barrier Studied Using an in Situ Brain Perfusion Technique , 1986, Annals of the New York Academy of Sciences.

[4]  Wei-Yin Loh,et al.  Classification and regression trees , 2011, WIREs Data Mining Knowl. Discov..

[5]  R. Didziapetris,et al.  Ionization‐Specific QSAR Models of Blood–Brain Penetration of Drugs , 2009, Chemistry & biodiversity.

[6]  W. Youden,et al.  Index for rating diagnostic tests , 1950, Cancer.

[7]  Michael H Abraham,et al.  The factors that influence permeation across the blood-brain barrier. , 2004, European journal of medicinal chemistry.

[8]  D. E. Clark.  In silico prediction of blood-brain barrier permeation. , 2003, Drug discovery today.

[9]  J. Platts,et al.  Correlation and prediction of a large blood-brain distribution data set--an LFER study. , 2001, European journal of medicinal chemistry.

[10]  Stephen A. Wring,et al.  Passive Permeability and P-Glycoprotein-Mediated Efflux Differentiate Central Nervous System (CNS) and Non-CNS Marketed Drugs , 2002, Journal of Pharmacology and Experimental Therapeutics.

[11]  S. Rapoport,et al.  Phenylalanine Transport Across the Blood‐Brain Barrier as Studied with the In Situ Brain Perfusion Technique , 1987, Journal of neurochemistry.

[12]  Yiyu Cheng,et al.  Identifying P-Glycoprotein Substrates Using a Support Vector Machine Optimized by a Particle Swarm , 2007, J. Chem. Inf. Model..

[13]  P. Borst,et al.  Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. , 1995, The Journal of clinical investigation.

[14]  P. Patsalos,et al.  The pharmacokinetic inter-relationship of tiagabine in blood, cerebrospinal fluid and brain extracellular fluid (frontal cortex and hippocampus) , 2004, Seizure.

[15]  Felix Hammann,et al.  Decision tree models for data mining in hit discovery , 2012, Expert opinion on drug discovery.

[16]  D. E. Clark,et al.  In Silico Predictions of Blood-Brain Barrier Penetration: Considerations to “Keep in Mind” , 2005, Journal of Pharmacology and Experimental Therapeutics.

[17]  A. Schinkel,et al.  Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. , 2003, Advanced drug delivery reviews.

[18]  Mikael Peräkylä,et al.  New energy terms for reduced protein models implemented in an off‐lattice force field , 2001, J. Comput. Chem..

[19]  M. Barrand,et al.  Localisation of breast cancer resistance protein in microvessel endothelium of human brain , 2002, Neuroreport.

[20]  D. E. Clark,et al.  Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 2. Prediction of blood-brain barrier penetration. , 1999, Journal of pharmaceutical sciences.

[21]  Jörg Huwyler,et al.  In silico prediction of brain and CSF permeation of small molecules using PLS regression models. , 2008, European journal of medicinal chemistry.

[22]  W. Pardridge,et al.  CNS Drug Design Based on Principles of Blood‐Brain Barrier Transport , 1998, Journal of neurochemistry.

[23]  N. White,et al.  Cerebral uptake of mefloquine enantiomers in fatal cerebral malaria. , 1999, International journal of clinical pharmacology and therapeutics.

[24]  N. Greig,et al.  Facilitated transport of melphalan at the rat blood-brain barrier by the large neutral amino acid carrier system. , 1987, Cancer research.

[25]  Denis M. Bayada,et al.  Polar Molecular Surface as a Dominating Determinant for Oral Absorption and Brain Penetration of Drugs , 1999, Pharmaceutical Research.

[26]  Y. Sawada,et al.  Comparison of blood-brain barrier permeability in mice and rats using in situ brain perfusion technique. , 2000, American journal of physiology. Heart and circulatory physiology.

[27]  J. Drewe,et al.  Endocytosis and Transcytosis of an Immunoliposome-Based Brain Drug Delivery System , 2000, Journal of drug targeting.

[28]  Andreas Maunz,et al.  Development of decision tree models for substrates, inhibitors, and inducers of p-glycoprotein. , 2009, Current drug metabolism.

[29]  Alexander Tropsha,et al.  Best Practices for QSAR Model Development, Validation, and Exploitation , 2010, Molecular informatics.

[30]  G. Theraulaz,et al.  Inspiration for optimization from social insect behaviour , 2000, Nature.

[31]  Egon L. Willighagen,et al.  The Chemistry Development Kit (CDK): An Open-Source Java Library for Chemo-and Bioinformatics , 2003, J. Chem. Inf. Comput. Sci..

[32]  Christophe Rousselle,et al.  Development of an In Situ Mouse Brain Perfusion Model and its Application to mdr1a P-Glycoprotein-Deficient Mice , 2000, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[33]  Jörg Huwyler,et al.  Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. , 2003, Journal of medicinal chemistry.

[34]  W. Pardridge,et al.  Capillary Depletion Method for Quantification of Blood–Brain Barrier Transport of Circulating Peptides and Plasma Proteins , 1990, Journal of neurochemistry.

[35]  D. Begley,et al.  Flavonoid permeability across an in situ model of the blood-brain barrier. , 2004, Free radical biology & medicine.

[36]  C. Daumas-Duport,et al.  ABC transporters, cytochromes P450 and their main transcription factors: expression at the human blood–brain barrier , 2008, Journal of neurochemistry.

[37]  Klaus R. Liedl,et al.  Qualitative prediction of blood–brain barrier permeability on a large and refined dataset , 2011, J. Comput. Aided Mol. Des..

[38]  Remigijus Didziapetris,et al.  Classification Analysis of P-Glycoprotein Substrate Specificity , 2003, Journal of drug targeting.

[39]  R. Waterhouse,et al.  Determination of lipophilicity and its use as a predictor of blood-brain barrier penetration of molecular imaging agents. , 2003, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.

[40]  W. Pardridge.  The blood-brain barrier: Bottleneck in brain drug development , 2005, NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics.

[41]  M. Yamazaki,et al.  Clinical Relevance of P-Glycoprotein in Drug Therapy , 2003, Drug metabolism reviews.

[42]  E. Lien,et al.  Structure–activity relationship: analyses of p‐glycoprotein substrates and inhibitors , 2003, Journal of clinical pharmacy and therapeutics.

[43]  Remigijus Didziapetris,et al.  Ionization-specific prediction of blood-brain permeability. , 2009, Journal of pharmaceutical sciences.

[44]  Peter Willett,et al.  Similarity-based virtual screening using 2D fingerprints. , 2006, Drug discovery today.

[45]  E. Hansson,et al.  Astrocyte–endothelial interactions at the blood–brain barrier , 2006, Nature Reviews Neuroscience.

[46]  Y. Sai,et al.  Limited distribution of new quinolone antibacterial agents into brain caused by multiple efflux transporters at the blood-brain barrier. , 2000, The Journal of pharmacology and experimental therapeutics.

[47]  W. Pardridge,et al.  Comparison of in vitro and in vivo models of drug transcytosis through the blood-brain barrier. , 1990, The Journal of pharmacology and experimental therapeutics.

[48]  Meihua Tu,et al.  Development of a computational approach to predict blood-brain barrier permeability. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[49]  C Helma,et al.  Prediction of Adverse Drug Reactions Using Decision Tree Modeling , 2010, Clinical pharmacology and therapeutics.

[50]  J R Chretien,et al.  Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors. , 1998, Journal of drug targeting.

[51]  D. E. Clark.  Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 1. Prediction of intestinal absorption. , 1999, Journal of pharmaceutical sciences.

[52]  Antony D. Gee,et al.  Drug Interactions with Lipid Membranes , 2009 .

[53]  S. Rapoport,et al.  An in situ brain perfusion technique to study cerebrovascular transport in the rat. , 1984, The American journal of physiology.

[54]  M. Melamed,et al.  Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[55]  S. Krähenbühl,et al.  Regulation of BCRP (ABCG2) and P-Glycoprotein (ABCB1) by Cytokines in a Model of the Human Blood–Brain Barrier , 2009, Cellular and Molecular Neurobiology.

[56]  V A Levin,et al.  Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. , 1980, Journal of medicinal chemistry.

[57]  Chris Morley,et al.  Open Babel: An open chemical toolbox , 2011, J. Cheminformatics.

[58]  James N. Morgan,et al.  The detection of interaction effects : a report on a computer program for the selection of optimal combinations of explanatory variables , 1964 .

[59]  A. Seelig,et al.  Blood-Brain Barrier Permeation: Molecular Parameters Governing Passive Diffusion , 1998, The Journal of Membrane Biology.

[60]  Peter Norvig,et al.  Artificial Intelligence: A Modern Approach , 1995 .

[61]  Jörg Huwyler,et al.  Combinatorial QSAR modeling of human intestinal absorption. , 2011, Molecular pharmaceutics.

[62]  W. Pardridge.  Transport of small molecules through the blood-brain barrier: biology and methodology. , 1995, Advanced drug delivery reviews.

[63]  U. Norinder,et al.  Computational approaches to the prediction of the blood-brain distribution. , 2002, Advanced drug delivery reviews.

[64]  Q. Smith,et al.  Brain Uptake of Nonsteroidal Anti-Inflammatory Drugs: Ibuprofen, Flurbiprofen, and Indomethacin , 2006, Pharmaceutical Research.

[65]  A. Avdeef,et al.  P-glycoprotein deficient mouse in situ blood-brain barrier permeability and its prediction using an in combo PAMPA model. , 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[66]  Harpreet S. Chadha,et al.  Molecular Factors Influencing Drug Transfer across the Blood‐Brain Barrier , 1997, The Journal of pharmacy and pharmacology.

[67]  J. Beijnen,et al.  Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient Mice. , 1996, Journal of the National Cancer Institute.

[68]  Jianzhong Liu,et al.  Prediction and mechanistic interpretation of human oral drug absorption using MI-QSAR analysis. , 2007, Molecular pharmaceutics.

[69]  M. Strolin Benedetti,et al.  Stereoselective and species-dependent kinetics of reboxetine in mouse and rat. , 1995, Chirality.

[70]  Jörg Huwyler,et al.  A Binary Ant Colony Optimization Classifier for Molecular Activities , 2011, J. Chem. Inf. Model..

[71]  Alexandre Varnek,et al.  Correlation of blood-brain penetration using structural descriptors. , 2006, Bioorganic & medicinal chemistry.

[72]  Phil Jeffrey,et al.  Central Nervous System Drug Disposition: The Relationship between in Situ Brain Permeability and Brain Free Fraction , 2007, Journal of Pharmacology and Experimental Therapeutics.